Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/18374
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Opat, Stephen | - |
dc.contributor.author | Hawkes, Eliza A | - |
dc.date | 2017-11-03 | - |
dc.date.accessioned | 2018-08-30T05:58:03Z | - |
dc.date.available | 2018-08-30T05:58:03Z | - |
dc.date.issued | 2017-12-20 | - |
dc.identifier.citation | Journal of Clinical Oncology 2017; 35(36): 4093-4094 | en |
dc.identifier.uri | https://ahro.austin.org.au/austinjspui/handle/1/18374 | - |
dc.language.iso | eng | - |
dc.title | Chemoimmunotherapy May Not Be Dead Yet in Chronic Lymphocytic Leukemia, But Fludarabine Plus Cyclophosphamide Plus Rituximab Is Potentially Facing Life Support. | - |
dc.type | Journal Article | - |
dc.identifier.journaltitle | Journal of Clinical Oncology | - |
dc.identifier.affiliation | Austin Health, Heidelberg, Victoria, Australia | en |
dc.identifier.affiliation | Monash University, Melbourne, Australia | en |
dc.identifier.affiliation | Monash Health, Clayton, Australia | en |
dc.identifier.affiliation | Eastern Health, Box Hill, Australia | en |
dc.identifier.doi | 10.1200/JCO.2017.75.4721 | - |
dc.identifier.pubmedid | 29099632 | - |
dc.type.austin | Journal Article | - |
local.name.researcher | Hawkes, Eliza A | |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.fulltext | No Fulltext | - |
item.grantfulltext | none | - |
item.languageiso639-1 | en | - |
item.openairetype | Journal Article | - |
crisitem.author.dept | Clinical Haematology | - |
crisitem.author.dept | Olivia Newton-John Cancer Wellness and Research Centre | - |
crisitem.author.dept | Olivia Newton-John Cancer Research Institute | - |
Appears in Collections: | Journal articles |
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.